Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 5/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20518475 | 0.97 | GBA1 (0.39) | SPHK2SPHK1HTTMEN1THRB | |
| SCHEMBL13106449 | 0.82 | MEN1 (0.45) | SPHK2SPHK1HTTMEN1THRB | |
| SCHEMBL11451186 | 0.82 | GBA1 (0.50) | HTTMEN1THRBKMT2AMAPT | |
| Ammonia Solution, Strong SCHEMBL14359739 | 0.80 | GBA1 (0.48) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL13107171 | 0.80 | TSHR (0.46) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL5987408 | 0.80 | — | — | |
| SCHEMBL28356186 | 0.79 | GBA1 (0.39) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL19698902 | 0.79 | EPHX2 (0.40) | SPHK1ALDH1A1TDP1GBA1EPHX2 | |
| SCHEMBL19705365 | 0.79 | EPHX2 (0.40) | SPHK1ALDH1A1TDP1GBA1EPHX2 | |
| SCHEMBL27905285 | 0.78 | MEN1 (0.50) | SPHK2SPHK1HTTMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4293035-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-3950698-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATE SITE | AJINOMOTO CO., INC. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20220010348-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE | AJINOMOTO CO., INC. (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3925964-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-20210371450-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | AJINOMOTO CO., INC. (JP) | 2021-02-16 | — | — | US | disclosed |
| EP-3398955-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220010348-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE | RNGTT, NUDT1, ADAR | SPHK2 2778/4885SPHK1 2922/4885HTT 646/4885 |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | NUDT1, RNGTT, POLN | SPHK2 1191/4885SPHK1 1100/4885HTT 1522/4885 |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | POLL, POLM, NUDT1 | SPHK2 1670/4885SPHK1 1166/4885HTT 3219/4885 |
| US-20210371450-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | RNGTT, DCLRE1B, PHOSPHO1 | SPHK2 1301/4885SPHK1 1313/4885HTT 1148/4885 |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, NOX4, POLRMT | SPHK2 1399/4885SPHK1 2211/4885HTT 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.